Publicaciones en colaboración con investigadores/as de Centro de Investigación Médica Aplicada (24)

2023

  1. Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031

  2. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  3. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161

  2. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study

    Blood Advances, Vol. 6, Núm. 3, pp. 976-992

  3. FlowCT for the analysis of large immunophenotypic data sets and biomarker discovery in cancer immunology

    Blood Advances, Vol. 6, Núm. 2, pp. 690-703

2021

  1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

  2. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

    Cancers, Vol. 13, Núm. 7

  3. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  4. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

  5. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis

    Blood Cancer Journal, Vol. 11, Núm. 2

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

    Leukemia, Vol. 34, Núm. 11, pp. 3007-3018

  3. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  4. Measurable residual disease in multiple myeloma: ready for clinical practice?

    Journal of hematology & oncology, Vol. 13, Núm. 1, pp. 82

  5. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

    Leukemia, Vol. 34, Núm. 2, pp. 589-603

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

  2. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers

    Journal of Immunological Methods, Vol. 475

  3. Immunophenotypic Pattern of De Novo Malignancy After Liver Transplantation

    Transplantation Proceedings, Vol. 51, Núm. 1, pp. 77-79

2018

  1. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

    Leukemia, Vol. 32, Núm. 4, pp. 874-881